Predicting the state’s high court would adopt the innovator liability theory, a Connecticut federal judge denied GlaxoSmithKline’s motion to dismiss a product liability suit alleging that a generic drug manufactured and sold by another company led to the death of a Cornell University student from Westport in 2018.

Alan Doran, on behalf of his daughter, Rachel Hope Doran, filed a lawsuit in U.S. District Court for the District of Connecticut against GlaxoSmithKline PLC and GlaxoSmithKline LLC (GSK) under the Connecticut Product Liability Act, alleging claims for design defect, failure to warn, and misleading advertising.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]